Credit Suisse Thinks Mednax Inc’s Stock is Going to Recover

By Carrie Williams

In a report released today, A.J. Rice from Credit Suisse maintained a Buy rating on Mednax Inc (MDResearch Report), with a price target of $42. The company’s shares opened today at $34.48, close to its 52-week low of $31.68.

According to TipRanks.com, Rice is a 5-star analyst with an average return of 9.6% and a 62.1% success rate. Rice covers the Services sector, focusing on stocks such as Quest Diagnostics Inc, Genesis Healthcare, and Acadia Healthcare.

Mednax Inc has an analyst consensus of Hold, with a price target consensus of $38.43.

See today’s analyst top recommended stocks >>

Mednax Inc’s market cap is currently $3.08B and has a P/E ratio of 11.77. The company has a Price to Book ratio of 1.02.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MEDNAX, Inc. provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The company’s solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.